165.0K NSE+BSE Volume
NSE 25 Apr, 2025 3:31 PM (IST)
OneSource Specialty Pharma Key Metrics
Check Before You Buy
VIEW FULL CHECKLISTLow rank
20.0% Pass in checklist
Check P/E Buy Sell Zone
Not enough data available
OneSource Specialty Pharma Stock Price Analysis
Day Price Range | 1557.9 (LTP) 1,4941,611.3 LowHigh |
Week Price Range | 1557.9 (LTP) 1,4941,664 LowHigh |
Month Price Range | 1557.9 (LTP) 1,319.51,763.7 LowHigh |
52 Week Price Range | 1557.9 (LTP) 1,2101,800 LowHigh |
OneSource Specialty Pharma Live Price Chart
OneSource Specialty Pharma Stock Analysis
OneSource Specialty Pharma stock analysis with key metrics, changes, and trends.
OneSource Specialty Pharma Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Stock Price | ₹1557.90 | -6.71% | negative |
| |
Quarterly Revenue | ₹397.96 Cr | 598.45% | positive |
| |
Quarterly Net profit | ₹68.85 Cr | 47.11% | positive |
| |
Mutual Fund Holding | 8.32 % | 3.7% | positive |
| |
Promoter Share Holding | 34.25 % | -3.52% | negative |
| |
Promoter Pledges | 20.06 % | 10.48% | negative |
|
Loading data..
Earnings Conference Calls, Investor Presentations and Annual Reports
OneSource Specialty Pharma Ltd. - Company Profile
What does OneSource Specialty Pharma Ltd. do?

OneSource Specialty Pharma is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. OneSource also offers end-to-end \Contract Development and Manufacturing Operations ('CDMO') services across all phases of pre-clinical and clinical development and commercial supply of biologics.
Website: www.onesourcecdmo.com
OneSource Specialty Pharma Ltd. Management structure
OneSource Specialty Pharma Ltd. - company history
Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of `Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The Company name was then changed to `Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies. The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as `Stelis Biopharma Limited' dated July 31, 2021,. Subsequently, the name was changed to its present `Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore. A Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024. Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively. Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, 2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies. In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re. 1/- each have been allotted and issued. At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers end-to-end Contract Development and Manufacturing Operations (CDMO) services across all phases of pre-clinical and clinical development and commercial supply of biologics. Company has 5 globally compliant Manufacturing Facilities. Customer list includes some of the top pharmaceutical generic companies, innovator pharmaceutical and biopharmaceutical companies, small biotechs and dedicated R&D houses, spread across the globe.